First Manhattan’s Galmed Pharmaceuticals GLMD Stock Holding History

First Manhattan’s Portfolio GLMD Stock Details GLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-722	Closed	-$1.55M	–	1409
2018 Q2	$1.55M	Buy	+722	New	+$1.05M	0.01%	391

Other funds holding GLMD

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return

Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

First Manhattan's GLMD Position: Q3 2018 in Review

First Manhattan sold out of Galmed Pharmaceuticals (GLMD) in Q3 2018, closing a stake of 722 shares — an estimated $1.55M sold.

First Manhattan first reported a position in GLMD in Q2 2018 and held it in 1 quarter. The position peaked at $1.55M in Q2 2018. 38 funds tracked by Wall St. Rank hold GLMD as of Q3 2018.

First Manhattan reported no remaining Galmed Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
First Manhattan sold 722 Galmed Pharmaceuticals shares in Q3 2018, an estimated $1.55M.
First Manhattan first reported a position in Galmed Pharmaceuticals in Q2 2018 and held it in 1 quarter.
First Manhattan's Galmed Pharmaceuticals position peaked at $1.55M in Q2 2018.
38 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q3 2018.

Based on First Manhattan's 13F filing for Q3 2018, filed 15 Oct 2018.